Friday, Mar 16, 2001
South San Francisco, Calif. -- March 16, 2001 --Genentech, Inc. (NYSE: DNA) and Actelion (SWX New Market: ATLN) announce that results of the companies' Phase III RITZ-2 (Randomized Intravenous Tezosentan) trial evaluating the ability of intravenous, dual endothelin receptor antagonist Veletri™ (tezosentan) to improve hemodynamics in patients with acute heart failure, will be presented on Tuesday, March 20 at the 50th Annual Scientific Session of the American College of Cardiology in Orlando, Fla.
The companies invite interested investors and the general public to listen to a discussion of the results via a live webcast at 11:00 AM EST from Genentech's website at http://www.gene.com. The webcast will be archived and available for replay until 1:00 PM EST on March 27, 2001.
Actelion Ltd, a biopharmaceutical company headquartered in Allschwil, Switzerland, is the global leader in creative science related to the endothelium -- the single layer of cells separating every blood vessel from the blood stream. Actelion concentrates on developing and bringing innovative drugs to patients. Tracleer™ and Veletri, its two flagship drugs, are in late stage development for several cardiovascular disorders, including chronic and acute heart failure as well as pulmonary arterial hypertension. In addition, Actelion is conducting drug discovery programs in cardiovascular diseases, malaria, Alzheimer's disease and cancer. Actelion is quoted on the Swiss Stock Exchange (SWX New Market: ATLN).
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Fourteen of the currently approved biotechnology products stem from Genentech science. Genentech markets nine biotechnology products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.
# # #